Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Anxiety and Depression Treatment Market Share, Size, Analysis, Trends: By Product: Antidepressant Drugs, Therapy and Devices; By Indication: Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Phobia, Others; Regional Analysis; Market Dynamics; Competitive Landscape; Industry Events and Developments; 2023-2028

Global Anxiety and Depression Treatment Market Outlook

The global anxiety and depression treatment market is projected to grow at a CAGR of 2.50% in the forecast period of 2023-2028 to reach a value of around USD 19.2 billion by 2027.

 

Therapy and Devices Segment to Propel the Market Growth of Anxiety and Depression Treatment

There is a growing adoption of therapies over anti-depressants due to the absence of side effects such as liver damage, epileptic fits, and heart problems, among others. In addition, the availability of different kinds of therapies such as Cognitive Behavioural Therapy, Dialectical Behavioural Therapy (DBT), and others are leading to the anxiety and depression treatment market growth.

 

The government initiatives to create awareness regarding psychotherapy and provide these services to the general population for treating anxiety and depression is significantly catalysing the market growth. For instance, the Improving Access to Psychological Therapies (IAPT) by the National Health Service, England aims towards treating anxiety and depression in England by training new therapists and deploying them in the services.

 

Further, the rising approvals of devices to treat anxiety and depression disorders such as the Cervella Cranial Electrotherapy Stimulator are expected to aid the market development.
 

North America to Account for a Significant Share in the Anxiety and Depression Treatment Market

The increasing prevalence of anxiety and depression disorders in the North American countries is leading to the market expansion. According to reports by the United States Center for Disease Control and Prevention, the number of adults with symptoms of anxiety or depression in the region has been increasing. In addition, there is a rise in approval of antidepressant drugs by the governmental organisations in the region, which is resulting in the market development.

 

Market Segmentation

Anxiety and depression are mental conditions that interfere with daily living. Anxiety is a feeling of excessive apprehension, fear, and worries about everyday situations. On the other hand, depression involves lowering one’s mood and negatively affects how a person thinks or acts. It is necessary to seek medical care and treatments in such conditions.

 

The anxiety and depression treatment market, by product, is divided into:

  • Antidepressant Drugs
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • Tricyclic Antidepressants (TCAs)
    • Monoamine Oxidase inhibitors (MAOIs)
    • Atypical Antipsychotics
    • Benzodiazepines
    • Anticonvulsants
    • Beta-Blockers
    • Others
  • Therapy and Devices
    • Fisher-Wallace stimulator
    • Transcranial Magnetic Stimulation (TMS)
    • Deep Brain Stimulation (DBS)
    • Vagus nerve stimulation (VNS)
    • Electroconvulsive Therapy (ECT)
    • Cognitive Behaviour Therapy (CBT)
    • Others

 

Based on indication, the market is segmented into:

  • Major Depressive Disorder (MDD)
  • Obsessive-Compulsive Disorder (OCD)
  • Phobia
  • Others

 

The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Increasing Cases of Anxiety and Depression, Developing Healthcare Infrastructure, Favourable Government Initiatives, and Drug Developments to Drive the Anxiety and Depression Treatment Market Growth

The increasing diagnosis owing to the developing healthcare infrastructure and the awareness among the population about the importance of the treatment and its efficiency is leading to the incremental market development of anxiety and depression treatment.

 

The COVID-19 pandemic bolstered the demand for anxiety and depression treatment as many people faced anxiety and depression disorders due to the prolonged confinement to their own houses and lowered social interactions.

 

In addition, the government initiatives for promoting mental health and preventing mental disorders are aiding the market growth of anxiety and depression treatment. In April 2021, the Government of India launched Mental Health and Normalcy Augmentation System to enhance the mental well-being of Indians.

 

Further, the innovative developments in the production of antidepressants by the leading market players to escalate their market potential are estimated to augment the market for anxiety and depression treatment.

 

Key Players in the Global Anxiety and Depression Treatment Market

The report gives an in-depth analysis of the key players in the market, covering their competitive landscape and latest developments like mergers, acquisitions, and investments, and plant turnarounds:

 

  • Pfizer
  • GlaxoSmithKline
  • Merck and Co. Inc
  • AstraZeneca
  • Eli Lily and Co.Johnson and Johnson
  • Forest Laboratories, Inc
  • Sanofi-Aventis
  • Others

 

The comprehensive EMR report offers an extensive assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2018-2022
Forecast Period 2023-2028
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product
  • Indication
  • Region
Breakup by Product
  • Antidepressant Drugs
  • Therapy and Devices
Breakup by Indication
  • Major Depressive Disorder (MDD)
  • Obsessive-Compulsive Disorder (OCD)
  • Phobia
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Pfizer
  • GlaxoSmithKline
  • Merck and Co. Inc
  • AstraZeneca
  • Eli Lily and Co.
  • Johnson and Johnson
  • Forest Laboratories, Inc
  • Sanofi-Aventis
  • Others

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Anxiety and Depression Treatment Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Anxiety and Depression Treatment Historical Market (2018-2022) 
    8.3    Global Anxiety and Depression Treatment Market Forecast (2023-2028)
    8.4    Global Anxiety and Depression Treatment Market by Product
        8.4.1    Antidepressant Drugs
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2018-2022)
            8.4.1.3    Forecast Trend (2023-2028)
            8.4.1.4    Market by Type
                8.4.1.4.1    Selective Serotonin Reuptake Inhibitors (SSRIs)
                8.4.1.4.2    Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
                8.4.1.4.3    Tricyclic Antidepressants (TCAs)
                8.4.1.4.4    Monoamine Oxidase inhibitors (MAOIs)
                8.4.1.4.5    Atypical Antipsychotics
                8.4.1.4.6    Benzodiazepines
                8.4.1.4.7    Anticonvulsants
                8.4.1.4.8    Beta-Blockers
                8.4.1.4.9    Others
        8.4.2    Therapy and Devices
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2018-2022)
            8.4.2.3    Forecast Trend (2023-2028)
            8.4.2.4    Market by Type
                8.4.2.4.1    Fisher-Wallace stimulator 
                8.4.2.4.2    Transcranial Magnetic Stimulation (TMS) 
                8.4.2.4.3    Deep Brain Stimulation (DBS) 
                8.4.2.4.4    Vagus nerve stimulation (VNS) 
                8.4.2.4.5    Electroconvulsive Therapy (ECT) 
                8.4.2.4.6    Cognitive Behaviour Therapy (CBT) 
                8.4.2.4.7    Others 
    8.5    Global Anxiety and Depression Treatment Market by Indication
        8.5.1    Major Depressive Disorder (MDD) 
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2018-2022)
            8.5.1.3    Forecast Trend (2023-2028)
        8.5.2    Obsessive-Compulsive Disorder (OCD) 
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2018-2022)
            8.5.2.3    Forecast Trend (2023-2028)
        8.5.3    Phobia 
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2018-2022)
            8.5.3.3    Forecast Trend (2023-2028)
        8.5.4    Others 
    8.6    Global Anxiety and Depression Treatment Market by Region
        8.6.1    Market Share
            8.6.1.1    North America
            8.6.1.2    Europe
            8.6.1.3    Asia Pacific
            8.6.1.4    Latin America
            8.6.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2018-2022)
        9.1.2    Forecast Trend (2023-2028)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2018-2022)
        9.2.2    Forecast Trend (2023-2028)
        9.2.3    Breakup by Country
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2018-2022)
        9.3.2    Forecast Trend (2023-2028)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2018-2022)
        9.4.2    Forecast Trend (2023-2028)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2018-2022)
        9.5.2    Forecast Trend (2023-2028)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    Pfizer
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    GlaxoSmithKline
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Merck and Co. Inc
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    AstraZeneca
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    Eli Lily and Co.
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    Johnson and Johnson
            12.2.6.1    Company Overview
            12.2.6.2    Product Portfolio
            12.2.6.3    Demographic Reach and Achievements
            12.2.6.4    Certifications
        12.2.7    Forest Laboratories, Inc
            12.2.7.1    Company Overview
            12.2.7.2    Product Portfolio
            12.2.7.3    Demographic Reach and Achievements
            12.2.7.4    Certifications
        12.2.8    Sanofi-Aventis
            12.2.8.1    Company Overview
            12.2.8.2    Product Portfolio
            12.2.8.3    Demographic Reach and Achievements
            12.2.8.4    Certifications
        12.2.9    Others
13    Industry Events and Developments

 

List of Figures and Tables

1.    Global Anxiety and Depression Treatment Market: Key Industry Highlights, 2018 and 2028
2.    Global Anxiety and Depression Treatment Historical Market: Breakup by Product (USD Billion), 2018-2022
3.    Global Anxiety and Depression Treatment Market Forecast: Breakup by Product (USD Billion), 2023-2028
4.    Global Anxiety and Depression Treatment Historical Market: Breakup by Indication (USD Billion), 2018-2022
5.    Global Anxiety and Depression Treatment Market Forecast: Breakup by Indication (USD Billion), 2023-2028
6.    Global Anxiety and Depression Treatment Historical Market: Breakup by Region (USD Billion), 2018-2022
7.    Global Anxiety and Depression Treatment Market Forecast: Breakup by Region (USD Billion), 2023-2028
8.    North America Anxiety and Depression Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
9.    North America Anxiety and Depression Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
10.    Europe Anxiety and Depression Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
11.    Europe Anxiety and Depression Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
12.    Asia Pacific Anxiety and Depression Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
13.    Asia Pacific Anxiety and Depression Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
14.    Latin America Anxiety and Depression Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
15.    Latin America Anxiety and Depression Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
16.    Middle East and Africa Anxiety and Depression Treatment Historical Market: Breakup by Country (USD Billion), 2018-2022
17.    Middle East and Africa Anxiety and Depression Treatment Market Forecast: Breakup by Country (USD Billion), 2023-2028
18.    Global Anxiety and Depression Treatment Market Structure

Key Questions Answered in the Report

The market is projected to grow at a CAGR of 2.50% between 2023 and 2028.

The market drivers are developing healthcare market, increasing diagnosis of mental conditions, awareness about the importance of treatments, and the rising inclination towards therapies.

The different signs and symptoms of anxiety are increased nervousness or restlessness, hyperventilation, increased heart rate, fatigue, and difficulty to focus or concentrate, among others.

Selective serotonin reuptake inhibitors offer a wide therapeutic range and is used to treat anxiety disorders and depression at the same time.

The key market trends include the growing cases of anxiety and depression disorders, government initiatives to promote the mental health, and the development of antidepressant drugs by leading market players.

The various products considered in the report are antidepressant drugs, therapy, and devices.

The different market divisions, based on indication, include major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and phobia, among others.

The players in the anxiety and depression treatment market are the Pfizer, GlaxoSmithKline, Merck and Co. Inc, AstraZeneca, Eli Lily and Co., Johnson and Johnson, Forest Laboratories, Inc, and Sanofi-Aventis, among others.

Purchase Full Report

Mini Report

$ 2199     $1799
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 3199     $2999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$ 4199     $3999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 5199     $4999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER